Last reviewed · How we verify
Propylene Glycol Preservative-free Artificial Tears
At a glance
| Generic name | Propylene Glycol Preservative-free Artificial Tears |
|---|---|
| Sponsor | Retina Research Institute, LLC |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period (PHASE4)
- Systane® Complete Preservative Free Lubricant Eye Drops (NA)
- Three Different Modalities for Treatment of Inflammatory Punctal Stenosis (NA)
- Evaluation of the Tolerability and Efficacy of CWT-f-002 Lubricant Eye Drops (NA)
- Topical Insulin in Neurotrophic Keratopathy After Diabetic Vitrectomy
- Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome (PHASE4)
- Evaluation of Lacrimal Punctal Changes by Anterior Segment Optical Coherence Tomography AS-OCT After Topical Combined Antibiotics and Steroids Treatment in Cases of Inflammatory Punctual Stenosis (PHASE4)
- Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: